お知らせ • May 15
Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 149,411,765
Price\Range: NZD 0.17
Transaction Features: Subsequent Direct Listing お知らせ • May 12
Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026 Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026 お知らせ • Nov 06
Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025 Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025 お知らせ • Jun 16
Pacific Edge Limited, Annual General Meeting, Aug 06, 2025 Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealand お知らせ • Jun 03
Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 150,000,000
Price\Range: NZD 0.1
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: NZD 0.1
Transaction Features: Subsequent Direct Listing お知らせ • May 31
Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: NZD 0.1 お知らせ • May 30
Pacific Edge Limited has filed a Follow-on Equity Offering. Pacific Edge Limited has filed a Follow-on Equity Offering.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: Subsequent Direct Listing お知らせ • May 12
Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025 Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025 お知らせ • Nov 06
Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024 Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024 お知らせ • May 07
Pacific Edge Limited, Annual General Meeting, Sep 24, 2024 Pacific Edge Limited, Annual General Meeting, Sep 24, 2024. お知らせ • May 01
Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024 Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024 お知らせ • Mar 14
Pacific Edge Limited Announces Board Changes Pacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors. お知らせ • Oct 19
Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023 Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023 お知らせ • Jun 09
Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023 Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success. New Risk • Jun 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$53.3m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (US$53.3m market cap).